This is a preview of subscription content, log in via an institution to check access.
Notes
2017 Canadian dollars
Reference
Nazha S, et al. Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence. Clinical Drug Investigation : 28 Sep 2018. Available from: URL: http://doi.org/10.1007/s40261-018-0705-6
Rights and permissions
About this article
Cite this article
Sunitinib cost effective for metastatic renal cell carcinoma. PharmacoEcon Outcomes News 814, 28 (2018). https://doi.org/10.1007/s40274-018-5371-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5371-7